Results 41 to 50 of about 5,158 (116)

¿Qué harías si fuera tu padre? Los beneficios de la comunicación empática oncólogo-paciente

Gaceta Mexicana de Oncología
Necesidad de una formación específica en comunicación… Se habla, pero no se hace
Rodrigo Lastra-del Prado, Marina Arribas-Velasco, Elisa Quílez-Bielsa   +2 more
doaj   +1 more source

Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors

Redox Biology, 2015
Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are overexpressed in the majority of renal cell carcinomas (RCC). This characteristic has supported the rationale of targeting VEGF-driven tumour vascularization, especially in clear cell
Luís A. Leon, Luís M. Antón-Aparicio
doaj   +1 more source

Systematic review of physical and dosimetric criteria for managing CIEDs in radiotherapy: A medical physicist's perspective

Journal of Applied Clinical Medical Physics, Volume 27, Issue 8, August 2026.
Abstract Aim Current radiotherapy (RT) guidelines for Cardiac Implantable Electronic Devices (CIEDs) are largely based on clinical management strategies and retrospective reports. This systematic review adopts a medical physics perspective to provide a critical, quantitative analysis of the technical evidence required for developing robust safety ...
Tiziana Malatesta, Agnese Barbareschi, Rita Alaimo, Emilio Mezzenga, Maria Grazia Brambilla, Anna Delana, Stefano Andreoli, Rita Consorti, Stefano Ren Kaiser, Marco Mapelli, Eugenia Moretti, Maria Mormile, Giulia Rambaldi Guidasci, Mara Severgnini, Lidia Strigari, Maria Daniela Falco   +15 more
wiley   +1 more source

Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansion

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract Background Vobramitamab duocarmazine is an investigational antibody–drug conjugate (ADC) targeting B7 homolog 3 (B7‐H3) with a cytotoxic duocarmycin‐based DNA‐alkylating payload. This study evaluated its safety and antitumor activity in advanced solid tumors.
Eugene Shenderov, Manish R. Sharma, Elena Garralda, John Powderly, Iwona Ługowska, Alexander Spira, Marc Cucurull Salamero, Sekwon Jang, Rasha Cosman, John Shen, Wen Xu, Piotr J. Wysocki, Rodryg Ramlau, Emmanuel S. Antonarakis, Andrew J. Weickhardt, Jakub Żołnierek, Emiliano Calvo, Enxu Zhao, Chet Bohac, Ashley Ward, Girish Mallesara   +20 more
wiley   +1 more source

Dissecting diffuse large B‐cell lymphoma heterogeneity: New insights from a state‐specific molecular characterisation

Clinical and Translational Medicine, Volume 16, Issue 8, August 2026.
Integrating DNA and RNA sequencing with digital deconvolution, this study identifies five malignant B‐cell states in DLBCL with distinct mutational and microenvironmental profiles. These states predict survival independently of standard indices, revealing a critical dichotomy between favourable TME‐dependent (S1) and aggressive TME‐independent (S5 ...
Robel Papotti, Filippo Vit, Tamara Bittolo, Federico Pozzo, Stefania Bettelli, Samantha Pozzi, Luca Braglia, Elisa Forti, Arianna Di Napoli, M. Christina Cox, Tamar Tadmor, Pellegrino Musto, Leonardo Flenghi, Martina Quintini, Giovanna R. Mansueto, Sara Galimberti, Valentina Donati, Michele Spina, Alberto Zamò, Andreas Rosenwald, Riccardo Bomben, Stefano Sacchi, Valter Gattei   +22 more
wiley   +1 more source

Prognostic Impact of Concomitant Genomic Alterations in FGFR2‐Positive Cholangiocarcinoma Treated With Pemigatinib

Liver International, Volume 46, Issue 8, August 2026.
ABSTRACT Background & Aims Anti‐FGFR therapies changed the treatment landscape for patients with previously treated, advanced, or metastatic cholangiocarcinoma (CCA) harbouring FGFR2 fusions/rearrangements. However, primary resistance to FGFR inhibitors remains a key challenge. In the present real‐world study, we aimed to evaluate the prognostic impact
Carolina Liguori, Riccardo Giampieri, Blandine Delaunay, Giada Pinterpe, Adelaide Mazzocca, Antoine Hollebecque, Jean Frederic Blanc, Mohamed Bouattour, Eric Assenat, Meher Ben Abdelghani, Matthieu Sarabi, Monica Niger, Caterina Vivaldi, Mario Mandalà, Andrea Palloni, Maria Bensi, Silvio Ken Garattini, David Tougeron, Pierre Combe, Massimiliano Salati, Margherita Rimini, Andrea Casadei‐Gardini, Chiara Alessandra Cella, Marco Tucci, Anna Diana, Elena Mori, Raffaella Longarini, Pascal Artru, Gael Roth, Ludovic Evesque, Agathe Vienne, Anthony Turpin, Sandrine Hiret, Vincent Bourgeois, Camille Herve, Rodolphe Paulon, Marion Stacoffe, David Malka, Matthieu Delaye, Julien Edeline, Astrid Lievre, Rosine Guimbaud, Rita Balsano, Nadim Fares, Rossana Berardi, Alessandro Parisi   +45 more
wiley   +1 more source

Evaluación de la eficacia del consejo nutricional y suplemento dietético en el control de la neuropatía periférica inducida por quimioterapia

Revista Médica Clínica Las Condes
Resumen: La neuropatía periférica inducida por quimioterapia (NPIQ) es un grupo heterogéneo de neuropatías producidas por los tratamientos oncológicos y es la complicación neurológica más frecuente relacionada con la quimioterapia.
Laura Fernández Madrigal, MD, Matilde Bolaños Naranjo, MD, Juan Bayo Calero, MD   +2 more
doaj   +1 more source

Real‐world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study

Cancer, Volume 132, Issue 14, 15 July 2026.
ABSTRACT Background Chemotherapy schemes have historically shown low efficacy in patients with metastatic melanoma and have been replaced by immunotherapy and targeted therapy. This work aimed to study whether chemotherapy remains an option after progression to immunotherapy in specific contexts.
Miguel‐Ángel Berciano‐Guerrero, Elisabeth Pérez‐Ruiz, Ainara Soria, Javier Medina Martínez, Pablo Ayala de Miguel, Eva Muñoz‐Couselo, Lorena Bellido, Rafael López Castro, Enrique Espinosa, Lourdes Gutiérrez Sanz, Pablo Cerezuela‐Fuentes, Almudena García Castaño, Guillermo Crespo, Teresa Puértolas, Carlos Aguado de la Rosa, Mónica Corral Subias, Begoña Campos Balea, Aida Bujosa Rodríguez, Victor Navarro Pérez, María José Lecumberri, Francisco Ramón García Arroyo, Alberto Jacobo Cunquero Tomás, Karmele Mujika, Luis Antonio Fernández, José Carlos Villa Guzmán, Berta Hernández, Joaquín Fra Rodríguez, José Luis Manzano, Salvador Martín Algarra, Iván Márquez‐Rodas   +29 more
wiley   +1 more source

Múltiples eventos relacionados con el esqueleto en una paciente con cáncer de mama

Revista de Osteoporosis y Metabolismo Mineral, 2013
Las metástasis óseas son frecuentes en el cáncer, apareciendo hasta en el 75% de las pacientes con cáncer de mama avanzado. Las complicaciones de las metástasis óseas incluyen dolor óseo, hipercalcemia y eventos relacionados con el esqueleto (EREs) como ...
Herrero Vicent C, Pascual Pla FJ, Samper Hiraldo JM, Gavilá Gregori J   +3 more
doaj  

An in-silico approach to predict and exploit synthetic lethality in cancer metabolism

Nature Communications, 2017
Exploiting synthetic lethality is a promising approach for cancer therapy. Here, the authors present an approach to identifying such interactions by finding genetic minimal cut sets (gMCSs) that block cancer proliferation, and apply it to study the ...
Iñigo Apaolaza, Edurne San José-Eneriz, Luis Tobalina, Estíbaliz Miranda, Leire Garate, Xabier Agirre, Felipe Prósper, Francisco J. Planes   +7 more
doaj   +1 more source